Brynne Underwood, Qiuhong Zhao, Alison R Walker, Alice S Mims, Sumithira Vasu, Meixiao Long, Tamanna Z Haque, Bradley W Blaser, Nicole R Grieselhuber, Sarah A Wall, Gregory K Behbehani, James S Blachly, Karilyn Larkin, John C Byrd, Ramiro Garzon, Tzu-Fei Wang, Bhavana Bhatnagar
{"title":"急性淋巴细胞白血病青少年和青年患者使用peg-天冬酰胺酶后静脉血栓的发生率。","authors":"Brynne Underwood, Qiuhong Zhao, Alison R Walker, Alice S Mims, Sumithira Vasu, Meixiao Long, Tamanna Z Haque, Bradley W Blaser, Nicole R Grieselhuber, Sarah A Wall, Gregory K Behbehani, James S Blachly, Karilyn Larkin, John C Byrd, Ramiro Garzon, Tzu-Fei Wang, Bhavana Bhatnagar","doi":"10.2217/ijh-2020-0009","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase.</p><p><strong>Materials & methods: </strong>Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed.</p><p><strong>Results: </strong>18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13-38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p = 0.003) after adjusting for gender.</p><p><strong>Conclusion: </strong>These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521187/pdf/","citationCount":"8","resultStr":"{\"title\":\"Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.\",\"authors\":\"Brynne Underwood, Qiuhong Zhao, Alison R Walker, Alice S Mims, Sumithira Vasu, Meixiao Long, Tamanna Z Haque, Bradley W Blaser, Nicole R Grieselhuber, Sarah A Wall, Gregory K Behbehani, James S Blachly, Karilyn Larkin, John C Byrd, Ramiro Garzon, Tzu-Fei Wang, Bhavana Bhatnagar\",\"doi\":\"10.2217/ijh-2020-0009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase.</p><p><strong>Materials & methods: </strong>Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed.</p><p><strong>Results: </strong>18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13-38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p = 0.003) after adjusting for gender.</p><p><strong>Conclusion: </strong>These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase.</p>\",\"PeriodicalId\":14166,\"journal\":{\"name\":\"International Journal of Hematologic Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521187/pdf/\",\"citationCount\":\"8\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Hematologic Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/ijh-2020-0009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ijh-2020-0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Aim: There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase.
Materials & methods: Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed.
Results: 18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13-38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p = 0.003) after adjusting for gender.
Conclusion: These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase.
期刊介绍：
International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
